JP2023536436A - ウイルス感染を治療するための組成物及び方法 - Google Patents

ウイルス感染を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2023536436A
JP2023536436A JP2023504816A JP2023504816A JP2023536436A JP 2023536436 A JP2023536436 A JP 2023536436A JP 2023504816 A JP2023504816 A JP 2023504816A JP 2023504816 A JP2023504816 A JP 2023504816A JP 2023536436 A JP2023536436 A JP 2023536436A
Authority
JP
Japan
Prior art keywords
peptide
seq
chimeric
blocking
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536436A5 (enExample
Inventor
ニール ピー． デサイ，
ジル ディビタ，
Original Assignee
アーディジェン， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーディジェン， エルエルシー filed Critical アーディジェン， エルエルシー
Publication of JP2023536436A publication Critical patent/JP2023536436A/ja
Publication of JP2023536436A5 publication Critical patent/JP2023536436A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023504816A 2020-07-24 2021-07-23 ウイルス感染を治療するための組成物及び方法 Pending JP2023536436A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2007849 2020-07-24
FR2007849 2020-07-24
PCT/US2021/043077 WO2022020782A1 (en) 2020-07-24 2021-07-23 Compositions and methods for treating viral infections

Publications (2)

Publication Number Publication Date
JP2023536436A true JP2023536436A (ja) 2023-08-25
JP2023536436A5 JP2023536436A5 (enExample) 2024-07-30

Family

ID=77398656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504816A Pending JP2023536436A (ja) 2020-07-24 2021-07-23 ウイルス感染を治療するための組成物及び方法

Country Status (8)

Country Link
US (1) US20230304010A1 (enExample)
EP (1) EP4185602A1 (enExample)
JP (1) JP2023536436A (enExample)
CN (1) CN116724059A (enExample)
AU (1) AU2021314336A1 (enExample)
CA (1) CA3190101A1 (enExample)
MX (1) MX2023001049A (enExample)
WO (1) WO2022020782A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3955967A4 (en) 2019-04-17 2023-06-07 Aadigen, LLC PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULES
WO2024187121A1 (en) * 2023-03-08 2024-09-12 Red Queen Therapeutics, Inc. Combination therapies comprising stabilized sars-cov-2 peptides
WO2024187174A2 (en) 2023-03-09 2024-09-12 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028497A2 (en) * 2003-09-15 2005-03-31 The Brigham And Women's Hospital Inc. Receptor binding peptides derived from the sars s protein
JP2019521659A (ja) * 2016-05-27 2019-08-08 アーディジェン， エルエルシー ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514530B2 (en) 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2012137036A1 (en) 2011-04-04 2012-10-11 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053880A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053881A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014053882A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
MX387665B (es) 2014-12-24 2025-03-18 Aadigen Llc Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos.
AU2018313940A1 (en) * 2017-08-10 2020-03-05 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028497A2 (en) * 2003-09-15 2005-03-31 The Brigham And Women's Hospital Inc. Receptor binding peptides derived from the sars s protein
JP2019521659A (ja) * 2016-05-27 2019-08-08 アーディジェン， エルエルシー ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS NANO, vol. 14, no. 4, JPN6025030857, 14 April 2020 (2020-04-14), pages 5143 - 5147, ISSN: 0005796900 *
ANTIVIRAL RESEARCH, vol. 94, no. 3, JPN6025030859, 2012, pages 288 - 296, ISSN: 0005650196 *
FUTURE MED CHEM., vol. 12, no. 18, JPN6025030856, 16 July 2020 (2020-07-16), pages 1647 - 1656, ISSN: 0005796899 *
UNIPROTKB/SWISS-PROT [ONLINE], vol. Accession No. Q9BYF1, JPN6025030858, 17 June 2020 (2020-06-17), pages 180, ISSN: 0005796901 *

Also Published As

Publication number Publication date
US20230304010A1 (en) 2023-09-28
AU2021314336A1 (en) 2023-03-09
WO2022020782A1 (en) 2022-01-27
CN116724059A (zh) 2023-09-08
MX2023001049A (es) 2023-04-11
CA3190101A1 (en) 2022-01-27
EP4185602A1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
US10688194B2 (en) Cell penetrating peptides for intracellular delivery of molecules
US10421784B2 (en) Cell penetrating peptides for intracellular delivery of molecules
EP2928906B1 (en) Cell penetrating peptides for intracellular delivery of molecules
CN101395180B (zh) 用作细胞穿膜肽的肽
AU2012206533B2 (en) Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
EP2694529B1 (en) Cell penetrating peptides for intracellular delivery of molecules
JP6709831B2 (ja) 血液脳関門を通過して輸送するための組成物及び方法
JP2023536436A (ja) ウイルス感染を治療するための組成物及び方法
WO2014053882A1 (en) Cell penetrating peptides for intracellular delivery of molecules
Ezzat et al. Peptide-based matrices as drug delivery vehicles
JP2011504375A (ja) 細胞の中に核酸を導入する医薬組成物及びその方法
Laufer et al. Selected strategies for the delivery of siRNA in vitro and in vivo
McCandless et al. Novel lung targeting cell penetrating peptides as vectors for delivery of therapeutics
CA2481979A1 (en) Peptides chemically modified with polyethylene glycol
CA2425769A1 (en) Novel peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260217